Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 January 2019 | Story Charlene Stanley | Photo Anja Aucamp
Dr Allessandra Kim Heggenstaller
Dr Allessandra Kim Heggenstaller’s doctoral thesis found that cosmetic surgery can lead to an enhanced sense of empowerment.

With human rights at the centre of our modern society’s psyche, the concept of women taking ownership of their own bodies is often interpreted as standing up against all forms of abuse as well as celebrating their own physical uniqueness.

But what about the interpretation that ownership also gives you the right to alter your physical appearance through cosmetic surgery?

The stigma traditionally surrounding cosmetic surgery which is purely done to correct a perceived physical flaw or shortcoming and not for health reasons, has always intrigued Alessandra Kim Heggenstaller. So much so, that the 31-year-old Sociology graduate made it the topic of her doctoral thesis (The role of cosmetic surgery in the embodied experience of female beauty).

 

Beauty and success

“Nowadays, the concept of human ‘beauty’ is intricately linked to that of identity: beauty is seen as

bringing success in occupation, love, and marriage. Accordingly, beauty is often treated as a commodity – social status is attributed to it, and negotiated with it,” says Heggenstaller.

She wanted to test the prevailing negative perception that women who opt for corrective surgery are vain and superficial and are motivated by their desire to fit into a stereotype of ‘the perfect female body’.

 

Surgery a last resort

In her research, Heggenstaller interviewed 10 Free State women who had cosmetic interventions.

The women were from various ages and backgrounds. However, Heggenstaller found certain commonalities:

“None of them did it for a male partner or to fit a perceived stereotype. All of them had done intensive research beforehand and for each of them surgery was really a last resort,” she says.

She found that the women’s main motivation was that they didn’t ‘feel at home’ in their own

bodies because of the perceived shortcoming.

“The study found that a cosmetic procedure was an action and choice that began a journey of change and self-discovery. When the physical body portrays a more accurate image of how the individual feels, she engages her lifeworld and social environment with an enhanced sense of empowerment,” says Heggenstaller.

 

No regrets

“It was also significant to hear that not one of my case studies had any regrets about opting for surgery. In fact, they all felt that they should have done it sooner.”

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept